PURE
Latest filing analyzed: 10-Q filed Jun 15, 2026 (103 days ago)
A newer filing may exist that we have not analyzed yet. This read reflects the last one in the ledger.
Company Intelligence Hub
Filing history, signal momentum, and bull/bear evolution
Chronological Filing Evolution (Click to filter / toggle)
Thesis (Bull Case Evolution)
The investment narrative has shifted from a pure-play technology bet to a race for survival and commercial validation. The company is attempting to leverage its EPA-registered SDC antimicrobial platform to capture the food safety and industrial disinfection markets. The appointment of new leadership and the securing of a $1 million private placement suggest a concerted effort to stabilize the balance sheet and pivot toward a more aggressive commercialization strategy.
Antithesis (Bear Case / Structural Risks)
The financial trajectory reveals a deepening debt spiral and systemic insolvency. The company's reliance on related-party convertible notes and a revolving credit line with a 10% interest rate highlights a desperate need for capital. With current liabilities far exceeding current assets, the company faces a high probability of massive shareholder dilution as it struggles to fund basic operations and meet debt covenants.
Synthesis (Verdict & Resolution)
PURE Bioscience is currently navigating a precarious transition from a development-stage entity to a commercial-scale provider of antimicrobial solutions. The latest filing reveals a company struggling with a severe liquidity crisis, evidenced by a formal going-concern warning and a stockholders' deficiency of $5.84 million. While the company has managed to maintain a high gross margin of 58% on its product sales, the absolute scale of revenue remains insufficient to cover the operational overhead and the weight of its debt obligations.
Core Takeaway
The company is growing its top line but is technically insolvent without further funding.
Investor Lens
A high-risk play on whether the SDC technology can scale fast enough to outrun the debt clock.
Watch Next
The outcome of the June 2026 note maturity and any further equity raises.
Calculated Financial Trajectory (Click to filter signals)
Signal Momentum Chart
Quarterly net bull/bear signal ratio. Click nodes to select a quarter.
Signal Timeline
No matching signals
Try adjusting or clearing active filters.
Filing History
The latest 10-Q filing for PURE Bioscience presents a company at a critical crossroads, balancing a viable product line against a failing financial structure. While the growth in net product sales and the maintenance of high gross margins provide a glimmer of hope, the sheer magnitude of the company's liabilities and the explicit warning regarding its ability to continue as a going concern dominate the narrative. The company is effectively racing against time to scale its revenue before its current cash reserves and related-party credit lines are exhausted. Investors are left to weigh the potential of the SDC antimicrobial platform against the immediate risks of insolvency and massive shareholder dilution. The recent capital raises and leadership changes indicate a desperate attempt to professionalize operations and secure a lifeline, but the fundamental challenge remains a lack of sufficient operating cash flow to cover the company's high fixed costs and debt service obligations.
Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.